Company intelligence / Profile preview

MonTa Biosciences

Kgs. Lyngby / Lyngby, Capital Region of Denmark, Denmarkmontabiosciences.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MonTa Biosciences’ lead candidate, MBS8, a lipid nanoparticle formulation containing a novel small molecule TLR7 agonist, has completed patient cohorts in an ongoing phase I clinical trial for solid tumors. The therapy has demonstrated superior anti-tumor activity in preclinical models and shows synergy with immune checkpoint inhibitors, radiotherapy, and chemotherapy. Over 45 patients have been treated as of mid-2024 at sites in Denmark, Belgium, and Spain[2][3].

Therapeutic areas: Oncology
Modalities: Lipid nanoparticle delivery therapySmall molecule
Industry: Biotech

Drug pipeline

1 asset

MBS8

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on MonTa Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MonTa Biosciences.

Explore the full profile